RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

United States168 participantsStarted 2024-06-25

Plain-language summary

The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).

Who can participate

Age range6 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Body surface area (BSA) affected by PSO ≥10%
✓. . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
✓. . Psoriasis Area and Severity Index (PASI) score ≥12 OR

What they're measuring

Psoriasis Area Severity Index 90 (PASI90) response at Week 16

Timeframe: Week 16

Investigator´s Global Assessment (IGA) 0/1 response at Week 16

Timeframe: Week 16

Trial details

NCT IDNCT06425549

SponsorUCB Biopharma SRL

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-08-21

Contact for this trial

UCB Cares

1-844-599-2273 (USA) ucbcares@ucb.com

View on ClinicalTrials.gov More Moderate to Severe Plaque Psoriasis trials